Vor Biopharma Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Vor Biopharma Inc. (VOR) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$296.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-11
- Vor Biopharma Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $8.80M, a 703.28% increase year-over-year.
- Vor Biopharma Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$9.10M.
- Vor Biopharma Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $6.21M, a 68.32% increase year-over-year.
- Vor Biopharma Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $5.00M, a 931.13% increase year-over-year.
- Vor Biopharma Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $10.93M, a 387.73% increase from fiscal 2024.
- Vor Biopharma Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $2.24M, a 21.37% decline from fiscal 2023.
- Vor Biopharma Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $2.85M, a 155.83% increase from fiscal 2022.
- Vor Biopharma Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $1.11M, a 175.06% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$296.00K 10-Q · filed 2026-08-11 | $5.91M derived: sum of 3 quarters · filed 2026-08-11 | $10.91M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$9.10M 10-Q · filed 2026-05-13 | -$2.89M derived: sum of 2 quarters · filed 2026-05-13 | $2.11M derived: sum of 3 quarters · filed 2026-05-13 | $3.20M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $6.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $11.21M derived: sum of 2 quarters · filed 2026-03-30 | $12.30M derived: sum of 3 quarters · filed 2026-08-11 | $10.93M 10-K · filed 2026-03-30 |
| 2025-09-30 | $5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $6.10M derived: sum of 2 quarters · filed 2026-08-11 | $4.72M 10-Q · filed 2025-11-13 | $8.41M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$277.00K 10-Q · filed 2026-08-11 | $3.41M derived: sum of 3 quarters · filed 2026-08-11 | $3.90M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$1.37M 10-Q · filed 2026-05-13 | $2.31M derived: sum of 2 quarters · filed 2026-05-13 | $2.80M derived: sum of 3 quarters · filed 2026-05-13 | $3.35M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $3.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $4.17M derived: sum of 2 quarters · filed 2026-03-30 | $4.72M derived: sum of 3 quarters · filed 2026-03-30 | $2.24M 10-K · filed 2026-03-30 |
| 2024-09-30 | $485.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.04M derived: sum of 2 quarters · filed 2025-11-13 | -$1.45M 10-Q · filed 2025-11-13 | -$1.27M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $551.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$1.93M 10-Q · filed 2025-08-12 | -$1.76M derived: sum of 3 quarters · filed 2025-08-12 | $900.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$2.48M 10-Q · filed 2025-05-14 | -$2.31M derived: sum of 2 quarters · filed 2025-05-14 | $349.00K derived: sum of 3 quarters · filed 2025-05-14 | $456.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $172.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $2.83M derived: sum of 2 quarters · filed 2025-03-20 | $2.94M derived: sum of 3 quarters · filed 2025-03-20 | $2.85M 10-K · filed 2025-03-20 |
| 2023-09-30 | $2.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $2.77M derived: sum of 2 quarters · filed 2024-11-07 | $2.68M 10-Q · filed 2024-11-07 | $4.33M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $107.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $19.00K 10-Q · filed 2024-08-08 | $1.68M derived: sum of 3 quarters · filed 2024-08-08 | $2.61M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$88.00K 10-Q · filed 2024-05-09 | $1.57M derived: sum of 2 quarters · filed 2024-05-09 | $2.50M derived: sum of 3 quarters · filed 2024-05-09 | $1.75M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $2.59M derived: sum of 2 quarters · filed 2024-03-20 | $1.84M derived: sum of 3 quarters · filed 2024-03-20 | $1.11M 10-K · filed 2024-03-20 |
| 2022-09-30 | $931.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $180.00K derived: sum of 2 quarters · filed 2023-11-07 | -$542.00K 10-Q · filed 2023-11-07 | -$470.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$751.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$1.47M 10-Q · filed 2023-08-10 | -$1.40M derived: sum of 3 quarters · filed 2023-08-10 | -$306.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$722.00K 10-Q · filed 2023-05-11 | -$650.00K derived: sum of 2 quarters · filed 2023-05-11 | $445.00K derived: sum of 3 quarters · filed 2023-05-11 | $2.13M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $72.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $1.17M derived: sum of 2 quarters · filed 2023-03-23 | $2.85M derived: sum of 3 quarters · filed 2023-03-23 | $405.00K 10-K · filed 2023-03-23 |
| 2021-09-30 | $1.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $2.78M derived: sum of 2 quarters · filed 2022-11-10 | $333.00K 10-Q · filed 2022-11-10 | $2.41M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $1.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$762.00K 10-Q · filed 2022-08-11 | $1.31M derived: sum of 3 quarters · filed 2022-08-11 | $4.02M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$2.44M 10-Q · filed 2022-05-12 | -$370.00K derived: sum of 2 quarters · filed 2022-05-12 | $2.34M derived: sum of 3 quarters · filed 2022-05-12 | $1.44M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $2.07M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $4.78M derived: sum of 2 quarters · filed 2022-03-14 | $3.89M derived: sum of 3 quarters · filed 2022-03-14 | $5.82M 10-K · filed 2022-03-14 |
| 2020-09-30 | $2.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $1.81M derived: sum of 2 quarters · filed 2021-11-10 | $3.75M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$893.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $1.04M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $1.93M 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |